These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38111295)

  • 21. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
    Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
    J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Reduced Enoxaparin Prophylactic Dosing on Bleeding and Thrombotic Risk for Low Body Weight Post-Operative Colorectal Surgery Patients.
    Cappetto CM; Dooley ER
    Hosp Pharm; 2024 Feb; 59(1):70-76. PubMed ID: 38223866
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients.
    Lee A; Badgley C; Lo M; Banez MT; Graff L; Damon L; Martin T; Dzundza J; Wong M; Olin R
    Bone Marrow Transplant; 2023 Nov; 58(11):1247-1253. PubMed ID: 37626267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Standard Versus Intermediate Prophylaxis Dose for Venous Thromboembolism Prophylaxis in Patients Hospitalized With COVID-19 Infection.
    Chakabva MS; Polina S; Brauner M; McGuire M; Brown Z; Akthar T; Todt M; Polina A; Nova FF
    Hosp Pharm; 2024 Feb; 59(1):94-101. PubMed ID: 38223865
    [No Abstract]   [Full Text] [Related]  

  • 25. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
    Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
    J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.
    Laporte S; Liotier J; Bertoletti L; Kleber FX; Pineo GF; Chapelle C; Moulin N; Mismetti P
    J Thromb Haemost; 2011 Mar; 9(3):464-72. PubMed ID: 21232002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
    Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early venous thromboembolism prophylaxis in patients with trauma intracranial hemorrhage: Analysis of the prospective multicenter Consortium of Leaders in Traumatic Thromboembolism study.
    Wu YT; Chien CY; Matsushima K; Schellenberg M; Inaba K; Moore EE; Sauaia A; Knudson MM; Martin MJ;
    J Trauma Acute Care Surg; 2023 Nov; 95(5):649-656. PubMed ID: 37314427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
    Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
    Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
    Deitelzweig SB; Becker R; Lin J; Benner J
    Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
    Amin AN; Lin J; Lenhart G; Schulman KL
    Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes associated with anti-Xa-monitored enoxaparin for venous thromboembolism prophylaxis.
    Saunders JA; Vazquez SR; Hill JA; Witt DM
    Pharmacotherapy; 2024 Mar; 44(3):224-230. PubMed ID: 38088033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin.
    Spinal Cord Injury Thromboprophylaxis Investigators
    J Trauma; 2003 Jun; 54(6):1111-5. PubMed ID: 12813331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
    Elsaid KA; Collins CM
    Am J Health Syst Pharm; 2012 Mar; 69(5):390-6. PubMed ID: 22345418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Hemodialysis Patients.
    Green MS; Tellor KB; Buckallew AR
    Hosp Pharm; 2017 Oct; 52(9):623-627. PubMed ID: 29276299
    [No Abstract]   [Full Text] [Related]  

  • 37. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.
    Wang TF; Milligan PE; Wong CA; Deal EN; Thoelke MS; Gage BF
    Thromb Haemost; 2014 Jan; 111(1):88-93. PubMed ID: 24136071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended Duration Enoxaparin Decreases the Rate of Venous Thromboembolic Events after Radical Cystectomy Compared to Inpatient Only Subcutaneous Heparin.
    Pariser JJ; Pearce SM; Anderson BB; Packiam VT; Prachand VN; Smith ND; Steinberg GD
    J Urol; 2017 Feb; 197(2):302-307. PubMed ID: 27569434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.
    Sherman DG; Albers GW; Bladin C; Fieschi C; Gabbai AA; Kase CS; O'Riordan W; Pineo GF;
    Lancet; 2007 Apr; 369(9570):1347-1355. PubMed ID: 17448820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.